Standard BioTools

Standard BioTools Current Assets

The Current Assets of Standard BioTools (LAB) as of Sep 21, 2026 is 440.83 M USD. In the previous year, Current Assets was 342.27 M USD — a change of 28.80% (higher).

Current Assets

440.83 MUSD

YoY

28.80%

Last updated:

Current Assets of Standard BioTools is 2026 440.83 M USD. Current Assets of Standard BioTools was 2025 342.27 M USD. It decreases by 28.80% higher compared to the previous year.

The Standard BioTools Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
129.21 M USD
Jan 1, 2019
96.12 M USD
Jan 1, 2020
117.64 M USD
Jan 1, 2021
72.05 M USD
Jan 1, 2022
208.84 M USD
Jan 1, 2023
158.56 M USD
Jan 1, 2024
342.27 M USD
Jan 1, 2025
440.83 M USD
The Standard BioTools Current Assets history
YEARCurrent AssetsYoY
440.83 MUSD+28.80%
342.27 MUSD+115.87%
158.56 MUSD-24.08%
208.84 MUSD+189.86%
72.05 MUSD-38.76%
117.64 MUSD+22.40%
96.12 MUSD-25.61%
129.21 MUSD+34.20%
96.28 MUSD-2.92%
99.18 MUSD-31.19%
144.14 MUSD-7.55%
155.91 MUSD+49.01%
104.63 MUSD+3.38%
101.21 MUSD+41.71%
71.42 MUSD+209.91%
23.05 MUSD-19.12%
28.49 MUSD-2.75%
29.30 MUSD-39.50%
48.43 MUSD+65.15%
29.32 MUSD
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Current Assets of Standard BioTools is 440.83 M USD in 2026.

Current Assets of Standard BioTools changed from 342.27 M USD to 440.83 M USD, representing a 28.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools